World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
58
Citations
12104
World Ranking
3520
National Ranking
1631

L F Fries publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where L F Fries sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 121 publications — 7th percentile

7% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

L F Fries D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where L F Fries sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 58 D-Index — 30th percentile

30% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

L F Fries is affiliated with Novavax in the United States and has focused their research primarily within the field of Medicine, contributing extensively to several subfields including Infectious Diseases, Epidemiology, Immunology, Public Health, Environmental and Occupational Health, and Radiology, Nuclear Medicine and Imaging.

Their recent research output features papers published mainly between 2020 and 2022, with significant contributions to the understanding of vaccine development and infectious disease control. Notable publications include:

  • Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (2020, New England Journal of Medicine)
  • SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice (2021, Nature Communications)
  • Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial (2021, The Lancet)
  • Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants (2020, New England Journal of Medicine)
  • Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial (2022, The Lancet Infectious Diseases)

L F Fries' work covers significant topics such as SARS-CoV-2 and COVID-19 research, COVID-19 clinical research studies, influenza virus research studies, monoclonal and polyclonal antibodies research, respiratory viral infections research, animal virus infections studies, and malaria research and control.

Throughout their career, Fries has commonly published in venues like bioRxiv (Cold Spring Harbor Laboratory), Journal of Infection, Microorganisms, Open Forum Infectious Diseases, and New England Journal of Medicine, indicating a broad dissemination of research findings across both preprint and peer-reviewed platforms.

Frequent collaborators in their research include Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Iksung Cho, and Gregory M. Glenn. These partnerships reflect contributions to numerous studies and vaccine development efforts with shared expertise.

Best Publications

  • Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.

    Cheryl Keech;Gary Albert;Iksung Cho;Andreana Robertson

  • The role of complement in inflammation and phagocytosis

    Michael M Frank;Louis F Fries

  • Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.

    Vivek Shinde;Sutika Bhikha;Zaheer Hoosain;Moherndran Archary

  • SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.

    Jing Hui Tian;Nita Patel;Robert Haupt;Haixia Zhou

  • Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

    Mehreen S Datoo;Magloire H Natama;Athanase Somé;Ousmane Traoré

  • Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants

    Shabir A Madhi;Fernando P Polack;Pedro A Piedra;Flor M Munoz

  • Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers

    Shelly A. McNeil;Scott A. Halperin;Joanne M. Langley;Bruce Smith

  • Plasma fibronectin enhances phagocytosis of opsonized particles by human peripheral blood monocytes.

    C G Pommier;S Inada;L F Fries;T Takahashi

  • Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy

    Louis F. Fries;Daniel M. Gordon;Roberta L. Richards;James E. Egan

  • Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade.

    L F Fries;H M Friedman;G H Cohen;R J Eisenberg

  • Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model.

    Milan Basta;Paul Kirshbom;Michael M. Frank;Louis F. Fries

  • A Recombinant Viruslike Particle Influenza A (H7N9) Vaccine

    Louis F. Fries;Gale E. Smith;Gregory M. Glenn

  • Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2.

    Roselyn J. Eisenberg;Manuel Ponce de Leon;Harvey M. Friedman;Louis F. Fries

  • A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age

    Gregory M. Glenn;Louis F. Fries;D. Nigel Thomas;Gale Smith

  • Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine

    Gregory M. Glenn;Gale Smith;Louis Fries;Rama Raghunandan

  • C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I.

    Louis F. Fries;Thelma A. Gaither;Carl H. Hammer;Michael M. Frank

  • Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines

    Ali Fattom;Yun Hee Cho;Chiayung Chu;Steven Fuller

  • Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.

    Gale E. Smith;David C. Flyer;Ramadevi Raghunandan;Ye Liu

  • Clinical Manifestations of Plasmodium falciparum Malaria Experimentally Induced by Mosquito Challenge

    L. W. Preston Church;Thong P. Le;Joe P. Bryan;Daniel M. Gordon

  • High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes

    Milan Basta;Louis F. Fries;Michael M. Frank

Frequent Co-Authors

Michael M. Frank
Michael M. Frank Duke University
Gale Smith
Gale Smith Novavax (United States)
Pedro A. Piedra
Pedro A. Piedra Baylor College of Medicine
David W. Vaughn
David W. Vaughn Bill & Melinda Gates Foundation
Mary Lou Clements
Mary Lou Clements Johns Hopkins University
Ruth A. Karron
Ruth A. Karron Johns Hopkins University
Bruce L. Innis
Bruce L. Innis GlaxoSmithKline (United Kingdom)
Brian R. Murphy
Brian R. Murphy National Institute of Allergy and Infectious Diseases
Paul T. Heath
Paul T. Heath St George's, University of London
Matthew B. Frieman
Matthew B. Frieman University of Maryland, Baltimore

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in immunology often intersects with various healthcare paths, including nursing and advanced practice roles. For those interested in expanding their clinical expertise, obtaining an acute care NP certification can open doors to specialized patient care, especially in acute settings.

Many students transitioning into immunology-related healthcare professions benefit from flexible education options. Programs like the accelerated NP programs offer a faster route to becoming a nurse practitioner, blending rigorous academics with practical experience.

For those without a nursing background, exploring online ABSN programs for non nurses provides a tailored pathway to enter nursing while balancing other commitments. These programs are designed to equip students with foundational nursing knowledge efficiently.

Additionally, if you're seeking quicker entry points into nursing, the easiest accelerated nursing programs can be a practical choice. These programs are known for simpler admission processes while maintaining quality education.

Combining immunology study with nursing credentials paves the way for impactful careers in healthcare, research, and patient care, offering diverse opportunities for growth and specialization.

Best Scientists Citing L F Fries

Trending Scientists

Recently Published Articles